Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Synthetic Lethality Druggable Genome RNAi Screen Identifies Genes Mediating Sensitivity To Lenalidomide In Multiple Myeloma Including RSK2

Yuan Xiao Zhu, Ph.D., Laura Bruins, Chang-Xin Shi, Ph.D., Jessica Schmidt, Chris Sereduk, Mia Champion, Ph.D., Esteban Braggio, Ph.D., Holly Yin, Ph.D., A. Keith Stewart, MBChB

Blood (2013) 122 (21): 3084.

https://doi.org/10.1182/blood.V122.21.3084.3084

Published: 2013

Journal Articles

Intracellular Accumulation Of Light Chains Caused By Lenalidomide, and Mediated Via CRBN, Causes Major ER Stress and Is Implicated In The Synergistic Combination Of Imids and Proteasome Inhibitors

Sinto Sebastian, Ph.D., Yuan Xiao Zhu, PhD, Esteban Braggio, Ph.D., Sonali Panchabhai, MBBS, Chang-Xin Shi, Ph.D., Gregory Ahmann, BS, Leif Bergsagel, M.D., Rafael Fonseca, M.D.

Blood (2013) 122 (21): 4434.

https://doi.org/10.1182/blood.V122.21.4434.4434

Published: 2013

Journal Articles

Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4

Yuan Xiao Zhu, Ph.D., Chang-Xin Shi, Ph.D., Laura Bruins, Klaus Martin Kortuem, MD, Jessica Schmidt, Xiu-Bao Chang, Ph.D., Esteban Braggio, Ph.D., Leif Bergsagel, M.D., Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 1807.

https://doi.org/10.1182/blood.V120.21.1807.1807

Published: 2012

Journal Articles

RNAi Screen of the Druggable Genome To Identify Modulators of Bortezomib in Myeloma.

Yuan Xiao Zhu, PhD, Holly Yin, Ph.D., Qiang Que, Ph.D., Rodger E. Tiedemann, M.D., Ph.D., Wee-Joo Chng, M.D., Chang Xin Shi, Ph.D., Spyro Mousses, Ph.D, Keith Stewart, M.D

Blood (2007) 110 (11): 2478.

https://doi.org/10.1182/blood.V110.11.2478.2478

Published: 2007

Journal Articles

Targeting Hematopoietic Cells Using a Blimp-1 Promoter Helper Dependent Adenoviruses.

Chang-Xin Shi, Ph.D, Xiao-Yan Wen, Ph.D, Ding-Yan Wang, Ph.D, Bo Gao, Ph.D, Gillian Sleep, Li-Hua Zhuang, Ph.D, Zhi-Hua Li, Mary M. Hitt, Ph.D, A. Keith Stewart, MD

Blood (2004) 104 (11): 5259.

https://doi.org/10.1182/blood.V104.11.5259.5259

Published: 2004

NARROW

A Synthetic Lethality Druggable Genome RNAi Screen Identifies Genes Mediating Sensitivity To Lenalidomide In Multiple Myeloma Including RSK2

Intracellular Accumulation Of Light Chains Caused By Lenalidomide, and Mediated Via CRBN, Causes Major ER Stress and Is Implicated In The Synergistic Combination Of Imids and Proteasome Inhibitors

Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4

RNAi Screen of the Druggable Genome To Identify Modulators of Bortezomib in Myeloma.

Targeting Hematopoietic Cells Using a Blimp-1 Promoter Helper Dependent Adenoviruses.

Email alerts

ASH Publications

American Society of Hematology

A Synthetic Lethality Druggable Genome RNAi Screen Identifies Genes Mediating Sensitivity To Lenalidomide In Multiple Myeloma Including RSK2

Intracellular Accumulation Of Light Chains Caused By Lenalidomide, and Mediated Via CRBN, Causes Major ER Stress and Is Implicated In The Synergistic Combination Of Imids and Proteasome Inhibitors

Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4

RNAi Screen of the Druggable Genome To Identify Modulators of Bortezomib in Myeloma.

Targeting Hematopoietic Cells Using a Blimp-1 Promoter Helper Dependent Adenoviruses.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only